Sinopharm China Bio-New Crown Inactivated Vaccine has no risk of thrombosis

August 19, 2021

Recently, Science Bulletin (Science Bulletin, Impact Factor: 11.780), an international authoritative natural science comprehensive academic journal, published Professor Qu Jieming, director of the Key Laboratory of Infectious Disease Emergency Prevention, Control, Diagnosis and Treatment, conducted a prospective study aimed at exploring whether the new crown inactivated vaccine can promote the production of thrombo-related autoantibodies and whether it will increase the risk of thrombotic events after vaccination. The study was carried out among 406 medical staff in Ruijin Hospital who had voluntarily vaccinated two doses of Sinopharm China Bio-New Crown Inactivated Vaccine and eliminated contraindications.

Homepage of Papers Published in "Science Bulletin" Journal

The new coronavirus vaccines currently used globally mainly include four categories: inactivated vaccines, nucleic acid vaccines, viral vector vaccines and genetic recombinant protein vaccines. Among them, inactivated vaccines are the most widely used in my country. A number of clinical studies and real-world data have confirmed the protective efficacy of inactivated vaccines. On May 7, 2021, the new crown inactivated vaccine of the Beijing Institute of Biological Products of Sinopharm Group was the first in the country to be included in the emergency use list by the World Health Organization for global epidemic protection. Since the new crown vaccine was put into use on a large scale, the safety of vaccination has been a concern. There are continuous reports of thrombocytopenia and arterial/venous thrombosis after vaccination with the new crown vaccine. Anti-platelet factor 4 antibodies were detected in the vaccinators. Its characteristics are similar to HIT. The researchers named it "vaccine-induced immune thrombotic platelets Reduced disease (VITT)". Whether the inactivated COVID-19 vaccine widely used in my country affects the production of thrombus-related autoantibodies and thrombotic events after vaccination is an important issue that urgently needs to be explored.

Research reveals: inactivated vaccination does not increase the risk of thrombotic events

In this prospective study, people who received two doses of the new crown inactivated vaccine (BBIBP-CorV, Beijing Biotechnology, three weeks apart) and agreed to receive peripheral blood collection before and after the vaccination were included in the study. Before the first dose of vaccination and 4 weeks after the second dose of vaccination, the basic information of the enrollees was collected, and blood routine, liver and kidney function, and anti-coronavirus antibody tests were performed. At the same time, peripheral blood samples were collected and serum was separated for thrombus-related autoantibodies. Spectrum detection. Detect 10 kinds of antibodies including IgG/M/A aCL, IgG/M/A aβ2GP1, IgG/M aPS/PT, aPF4-heparin and ANA through internationally accepted kits and detection methods, and follow-up observation of thrombotic events . The results showed that before the first dose of inactivated COVID-19 vaccine, the positive rate of COVID-19 antibodies in the group was 0, and 4 weeks after the second dose of vaccine, the seroconversion rate of COVID-19 antibodies was 95.81% (389/406). There was no significant difference in the positive rate of autoantibodies and the level of antibodies in the samples collected before and after vaccination. During the follow-up period of at least 8 weeks, none of the enrolled patients experienced thrombotic events and thrombocytopenia. Therefore, the new coronavirus inactivated vaccine did not affect the levels of anti-phospholipid antibodies and anti-PF4-heparin antibodies, and at the same time did not increase the risk of thrombosis.

Schematic diagram of research content

Through the detection of autoantibody profiles in samples before and after vaccination and long-term follow-up of the participants, the research results provide a theoretical basis for the safety of the new crown inactivated vaccine and help build public confidence in the new crown vaccine and the popularization of the new crown vaccine . At present, Sinopharm China Bio-New Crown Inactivated Vaccine has been registered and marketed in 9 countries including China, UAE, Bahrain, Bolivia, Seychelles, Thailand, Turkmenistan, Malaysia, Peru, 98 countries and regions and international organizations have approved emergency use Or market access, more than 100 countries have clearly stated their use needs, and the vaccinated population has covered 196 countries.

문의하기

Author:

Ms. Yi

Phone/WhatsApp:

+8618888297294